Venkataraman V - Search Results

1

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Cote GM, Haddox CL, Choy E, Merriam PA, Mazzola E, Venkataraman V, Alcindor T, Wagner AJ, Demetri GD, George S. Cote GM, et al. Among authors: venkataraman v. Clin Cancer Res. 2024 Jul 1;30(13):2702-2708. doi: 10.1158/1078-0432.CCR-24-1037. Clin Cancer Res. 2024. PMID: 38723278 Clinical Trial.

2

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.

Venkataraman V, George S, Cote GM. Venkataraman V, et al. Oncologist. 2023 Aug 3;28(8):671-681. doi: 10.1093/oncolo/oyad167. Oncologist. 2023. PMID: 37315115 Free PMC article. Review.

3

Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality.

Venkataraman V, Martin-Giacalone BA, Drake BF, Salmi L, Claus EB, Schuster ALR, Bridges JFP, Lenz HJ, Willman CL, Diehl D, Janeway KA, Mack JW, George S. Venkataraman V, et al. J Clin Oncol. 2024 Dec;42(34):4018-4022. doi: 10.1200/JCO.24.00347. Epub 2024 Aug 2. J Clin Oncol. 2024. PMID: 39094073 No abstract available.

4

Blast and accelerated phase CML: room for improvement.

How J, Venkataraman V, Hobbs GS. How J, et al. Among authors: venkataraman v. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):122-128. doi: 10.1182/hematology.2021000240. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889372 Free PMC article.

5

Hyperfibrinolysis during the treatment of rhabdomyosarcoma.

Taylor SR, Connors JM, Venkataraman V. Taylor SR, et al. Among authors: venkataraman v. Res Pract Thromb Haemost. 2024 May 31;8(4):102467. doi: 10.1016/j.rpth.2024.102467. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 39040518 Free PMC article.

6

Arsenic toxicity manifesting as profuse watery diarrhea during induction therapy for acute promyelocytic leukemia.

Ott A, Venkataraman V, Badran YR, Goldman R, Spasic S, Vyas DA, Amrein P, McAfee S, Brunner A, Fathi AT, Narayan R. Ott A, et al. Among authors: venkataraman v. Clin Case Rep. 2021 May 15;9(5):e04115. doi: 10.1002/ccr3.4115. eCollection 2021 May. Clin Case Rep. 2021. PMID: 34026155 Free PMC article.

7

Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors.

Venkataraman V, Bales JR, Signorelli J, Hobbs GS. Venkataraman V, et al. J Oncol Pharm Pract. 2023 Jul;29(5):1119-1124. doi: 10.1177/10781552221098044. Epub 2022 May 2. J Oncol Pharm Pract. 2023. PMID: 35491703

8

Secondary histiocytic sarcoma with BRAF^V600E mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy.

Venkataraman V, Massoth LR, Sullivan RJ, Friedmann AM. Venkataraman V, et al. Pediatr Blood Cancer. 2021 Oct;68(10):e29166. doi: 10.1002/pbc.29166. Epub 2021 Jun 1. Pediatr Blood Cancer. 2021. PMID: 34061432 No abstract available.

9

Setting Intentions.

Venkataraman V. Venkataraman V. JAMA. 2024 Jan 23;331(4):287-288. doi: 10.1001/jama.2023.26823. JAMA. 2024. PMID: 38180774

10

Secondary histiocytic sarcoma with BRAF^V600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib.

Venkataraman V, Massoth LR, Sullivan RJ, Friedmann AM. Venkataraman V, et al. Pediatr Blood Cancer. 2020 May;67(5):e28200. doi: 10.1002/pbc.28200. Epub 2020 Feb 9. Pediatr Blood Cancer. 2020. PMID: 32037654 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191 results

Search Page

Filters